The Efficacy and Safety of At-home Transcutaneous Electrical Nerve Stimulation in Insomnia

Insomnia Clinical Trial

Official title:

Pilot Study to Explore the Efficacy and Safety of At-home Transcutaneous Electrical Nerve Stimulation in Insomnia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05546112
• Other study ID #: YB-05
• Status: Not yet recruiting
• Phase: N/A
• Start date: October 4, 2022
• Est. completion date: December 31, 2022

Study information

• Verified date: September 2022
• Source: Ybrain Inc.
• Contact: Kiwon Lee, PhD
• Phone: +82-535-2871
• Email: clinical.trials[@]ybrain.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to explore the effects and safety of transcutaneous electrical nerve stimulation (TENS) at home for patients diagnosed with insomnia on the improvement of insomnia and nervous stability.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 65 Years

Eligibility

Inclusion Criteria:

• Men and women between the ages of 19 and under 65

• Those who meet the criteria for the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) for Insomnia

• Those with a score of 8 or higher based on the Korean version Insomnia severity index (ISI-K)

• A person whose sleeping environment and habits are regular, usually between 9:00 p.m. and 1:00 a.m., go to bed, lie down for 7 to 10 hours, and wake up between 5 and 10 a.m.

• In the case of patients who regularly take drugs for improving insomnia at least once a week, those who agree to discontinue taking the prohibited drugs in this study for a total of 5 weeks, 1 week to remove the drug effect after screening and 4 weeks for the clinical study period

• Persons who do not have a reason to prohibit the use of electrotherapy that can significantly affect biomarkers in relation to this study

• A person who voluntarily decides to participate and agrees in writing to abide by the precautions after hearing and understanding a sufficient explanation about this clinical trial

Exclusion Criteria:

• Those who have been diagnosed with sleep arousal disorders other than insomnia (hypersomnia disorder, narcolepsy, breathing-related sleep disorder, circadian rhythm sleep arousal disorder, parasomnia)

• Those who have insomnia due to physical illness or medications being taken

• Patients with major medical and neuropsychiatric diseases other than sleep disorders

• Persons who have had or are currently undergoing dental treatment with a history of implanting metallic materials into the upper body, such as the transcranial or face, neck, etc., where non-invasive electrical stimulation is difficult or impossible

• Compliance was evaluated by writing a sleep diary for 1 week from the start of treatment, and if a sleep diary of 3 days or less was kept for 1 week, it was excluded from the study.

• Those who have changed the type and dose of drugs used within the last 3 months, or the type and time of cognitive behavioral therapy

• If you are currently registered in another clinical trial or use another clinical trial drug or device within 60 days from the time of screening

Exclusion criteria prior to intervention (After the sleep diary for one week after the screening test, if the following criteria are met, the patient will be excluded from participation in the study before the intervention.)

• Those with less than 8 points based on the Korean version of Insomnia severity index (ISI-K)

• When writing a sleep diary for a week, if it is written for less than 3 days or has an irregular sleep schedule

Related Conditions & MeSH terms

• Insomnia
• Sleep Initiation and Maintenance Disorders

Intervention

Device:
• Transcutaneous Trigeminal Electrical Nerve Stimulation using YPS-401B
A device that improves insomnia symptoms by transcutaneously applying electrical stimulation including a pulse (10 kHz) burst waveform (10 Hz) to the forehead area to the trigeminal nerve
• Sham Stimulation using YPS-401B
A device that is attached in the same way as a real medical device, but actually applies a shum stimulus

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Ybrain Inc.	Seoul National University Bundang Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in Insomnia Severity Index (ISI)	Changes in Insomnia Severity Index (ISI) after 4 weeks from pretreatment:	after 4 weeks
Secondary	Remission rate of ISI	Remission rate of ISI after 4 weeks compared to before treatment (Remission: ISI score of 7 or less)	after 4 weeks
Secondary	Response rate of ISI	Response rate of ISI after 4 weeks compared to before treatment (Response: ISI change of more than 7 points or 50% or more decrease)	after 4 weeks
Secondary	Changes in Pittsburgh Slepp Quality Index (PSQI)	Changes in Pittsburgh Slepp Quality Index (PSQI) after 4 weeks compared to before treatment	after 4 weeks
Secondary	Changes in index of slepp diary	Changes in index of sleep diary (sleep latency, bedtime, sleep time) after 4 weeks compared to before treatment	after 4 weeks
Secondary	Changes in EEG index	Changes in EEG index (absolute power, relative power) after 4 weeks compared to before treatment	after 4 weeks